UroGen Pharma Ltd
For the period ended Mar 31, 2024. Filed May 13, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 13, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Other Information
Item5. Other Information.
On* March 15, 2024,our Chief Medical Officer, Mark Schoenberg, terminated the trading plan previously entered into on December 26, 2023,to sell up to 30,000 ordinary shares. This plan was intended to satisfy the affirmative defense conditions of Rule10b5*-1(c) under the Exchange Act.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.